A novel taspine analog, HMQ1611, inhibits growth of non-small cell lung cancer by inhibiting angiogenesis

Oncology Letters

Volumn 4, Issue 5, 2012, Pages 1109-1113

  Lu, Wen ^a   Dai, Bingling ^a   Ma, Weina ^a   Zhang, Yanmin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

A549 cell; Angiogenesis; HMQ1611; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HMQ1611; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSAY; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL EXAMINATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PROTEIN SECRETION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84866099909     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.855     Document Type: Article

References (23)

1. Folkman J: Anti-angiogenesis: a new concept for therapy of solid tumors. Ann Surg 175: 409-416, 1972.
2. Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9: 2-10, 2004.
3. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
4. Hirte H: Novel developments in angiogenesis cancer therapy. Curr Oncol 16: 50-54, 2009.
5. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
6. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993.
7. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
8. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y and YasumotoK: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115: 1007-1014, 1998.
9. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
10. Carney DN: Lung cancer-time to move on from chemotherapy. N Engl J Med 346: 126-128, 2002.
11. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A and Wirtz CR: Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumors. Cancer Treat Rev 32: 74-89, 2006.
12. Harding J and Burtness B: Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 41: 107-127, 2005.
13. Glade Bender J, Cooney EM, Kandel JJ and Yamashiro DJ: Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 7: 289-300, 2004.
14. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 438: 932-936, 2005.
15. Ribatti D: Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treatment Rev 37: 344-352, 2011.
16. Jekunen AP and Kairemo KJA: Inhibition of malignant angiogenesis. Cancer Treat Rev 23: 263-266, 1997.
17. Zhang Y, He L, Meng L and Luo W: Taspine isolated from Radix et Rhizoma Leonticis inhibits proliferation and migration of endothelial cells as well as chicken chorioallantoic membrane neovascularisation. Vascul Pharmacol l48: 129-137, 2008.
18. Zhang YM, He LC and Wang HY: Inhibitory effect of taspine on mouse S180 sarcoma and its mechanism. Zhongguo Zhong Yao Za Zhi 32: 953-956, 2007 (In Chinese).
19. Zhang Y, He L and Zhou Y: Taspine isolated from Radix et Rhizoma Leonticis inhibits growth of human umbilical vein endothelial cell (HUVEC) by inducing its apoptosis. Phytomedicine 15: 112-119, 2008.
20. Grepin R and Pages G: Molecular mechanisms of resistance to tumor antiangiogenic strategies. J Oncol 2010: 835680, 2010.
21. Ellis LM: Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 18: 1007-1021, 2004.
22. Jain RK: Molecular regulation of vessel maturation. Nat Med 9: 685-693, 2003.
23. Rousseau S, Houle F, Landry J and Huot J: p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15: 2169-2177, 1997.